Feedback to FDA: Human gene therapy for neurodegenerative diseases: draft guidance for industry

A cross collaboration of members participated in a series of meetings to review FDA Human gene therapy for neurodegenerative diseases: draft guidance for industry which was published for public consultation January 2021.

A summary document detailing consolidated feedback and suggested recommendations that represented the views of member companies was submitted to the FDA in April 2021 for consideration prior to finalizing.

This document is reserved for the use of BioPhorum members only.

I don't have access to this document

Make a selection below and submit your request. We will get back to you ASAP.

My company would like to become a member

If you're not sure if your company is a member of this Phorum, or if you would like to enquire on behalf of your company about becoming a member, please see our membership page.

Preview